NCT05995366View on ClinicalTrials.gov

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Healthy Volunteer
Interventions
DRUG

ABBV-903

Solution; Oral

Trial Locations (1)

53704

Fortrea Clinical Research Unit Inc. /ID# 253962, Madison

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY